Resources | Neulasta® (pegfilgrastim) Onpro®

Neulasta® (pegfilgrastim) is a prescription medicine used to help reduce the... Read More

You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional and would like to return to the consumer site, please click CANCEL.

Resources for patients on Neulasta® Onpro® and their caregivers

Find support in the cancer community

There are organizations all over the country that can provide information and support during your cancer journey and beyond.* Start here to find resources in your area.

*These third-party resources are for your information only. Amgen does not endorse and is not responsible for the content included in these resources.

American Cancer Society® (ACS)

News, information, and support.

Phone (toll-free): 800-227-2345
Cancer Hope Network

National, nonprofit organization offering free and confidential one-on-one emotional support to adult patients with cancer and their families.

Phone (toll-free): 1-877-467-3638
Cancer Support Community®

Support, education, and research for people living with cancer.

Phone: 202-659-9709 or toll-free 888-793-9355
National Cancer Institute (NCI)

The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training.

Phone (toll-free): 800-4-CANCER (800-422-6237)
National Comprehensive Cancer Network® (NCCN®)

Alliance of leading cancer centers that offers patient education resources and assistance information, including disease-specific treatment guidelines.

Phone: 215-690-0300
Patient Advocate Foundation (PAF)

Direct case management, education, and financial support for people living with chronic and debilitating diseases.

Phone: 800-532-5274
Prevent Cancer Foundation (PCF)

Nonprofit dedicated to saving lives through cancer prevention and early detection.

Phone (toll-free): 800-227-2732
Expand List
Collapse List

Injector Disposal Program

The Sharps Disposal Container Program helps you easily and safely dispose of the on-body injector for Neulasta® at no additional cost. You can sign up as soon as your doctor prescribes Neulasta® Onpro®. If you have additional questions about the Sharps Disposal Container Program, call 1‑844‑MYNEULASTA (1‑844‑696‑3852).

Has your doctor prescribed the Neulasta® Onpro® kit, which includes the on-body injector for Neulasta®?

(You must be 18 years of age or older to participate.)

Privacy Notice and Authorization

*Please read and accept the Privacy Notice.

Amgen’s Patient Authorization

Uses and Disclosure of Personal Information

I authorize Amgen and its contractors and business partners (“Amgen”) to use and/or disclose my personal information, including my personal health information, only for the following purposes:

To operate, administer, enroll me in, and/or continue my participation in Amgen’s Neulasta® informational program or any other Amgen-affiliated patient support services and activities related to my condition or treatment (for example, Sharps Disposal Container program, co-pay card programs, reimbursement assistance programs, drug coverage verification, nurse educator services, adherence program and disease management support);

To contact, with my permission, my doctor and the rest of my health care team and share with them my health information that may be useful for my care;

To provide me with informational and promotional materials relating to Amgen products and services, and/or my condition or treatment; and/or

To improve, develop, and evaluate products, services, materials and programs related to my condition or treatment.

In order for Amgen to provide me with the services and/or programs described above, Amgen needs to collect and use my personal information, including my personal health information. I understand that my personal health information may include any information, in electronic or physical form, in the possession of or derived from a health care provider, health care plan, pharmacy, pharmaceutical company, laboratory and/or their contractor (“Health Care Provider”). This may include select information from or about my medical history and general health, my health care plan benefits, payment limits or restrictions covered by my health care plan policy, and/or my adherence to my treatment.

I authorize my Health Care Providers to disclose my personal health information to Amgen, and between themselves, as necessary, but only for the purposes stated above in this Authorization. I understand that certain of my Health Care Providers (such as pharmacies and specialty pharmacies) may receive remuneration from Amgen in exchange for disclosing my personal health information and/or for using my information to contact me with communications about Amgen products which have been prescribed to me (for example medication reminder programs) and other patient support services.

Expiration, Right to Obtain a Copy and Right to Cancel

I understand that by signing this form, I authorize my Health Care Providers or others who might hold my health information to only release it to Amgen employees, as well as to its contractors and business partners, who are performing the services set forth in this Authorization. I also understand I am authorizing my personal information, including my personal health information, to be used for the purposes described above. I understand and agree that by signing below, I am authorizing those who rely on this Authorization to release my personal health information for the earlier of five (5) years or until my participation in the program ends through my cancellation, unless a shorter time period is required by state law.

I understand that I can obtain a copy of this Authorization or cancel this Authorization at any time by calling Amgen at 800-224-7276 or by writing to PO Box 681308 Indianapolis, IN 46268. If I cancel my consent, I will no longer qualify for the services described. I also understand that if a Health Care Provider is disclosing my personal health information to Amgen on an authorized on-going basis, my cancellation with Amgen will be effective with respect to any such Health Care Providers as soon as they receive notice of my cancellation.

No Effect on Treatment

I understand I do not have to sign this Authorization and that my enrollment in any of the services and/or programs described above is entirely voluntary. I understand that Amgen, as well as Health Care Providers, cannot require me, as a condition of having access to medications, prescription drugs, treatment or other care, to sign this Authorization. Federal Law (including HIPAA) requires a signed authorization in order for Amgen to collect this information from my Health Care Providers. I understand I cannot participate in the listed services and/or programs without signing this Authorization or an equivalent authorization with my Health Care Providers.

Information Received from Health Care Providers

I understand that once my personal health information has been disclosed to Amgen, federal privacy laws may no longer apply and protect it from further disclosure. Amgen agrees, however, to protect my personal health information by only using and disclosing it as stated in the Authorization or as otherwise allowed or required by law.

Authorization to Contact

I understand and consent to Amgen contacting me using the contact information provided in this form to enroll me in, operate, and administer Amgen patient support services and/or programs as described above other than promotional communications by telephone or SMS/text (which I can separately opt-in below). I understand that the operation and administration of certain of these services and/or programs may require that Amgen contact me by telephone or SMS/text.

I am entitled to receive a copy of my authorization. Print this page.

I give Amgen permission to contact me by email, phone, mail, and/or SMS/text message for the purposes detailed in the Privacy Notice above, and to provide me with informational and marketing communications in the future.

Please note: If you do not want your Personal Information used for the purposes described above, click the Cancel button to discontinue your registration.

This is a security feature to enhance your protection.


Glossary of Chemo & Cancer Terms

This list of terms will help you better understand your cancer treatment.

Absolute neutrophil count (ANC) – ANC refers to the total number of neutrophils present in the blood. Neutrophils are particularly important because they defend our bodies against certain types of infection.

Bacteria – Microscopic (can only be seen with a microscope) organisms (living things) that live in and around most living and nonliving things. Some types of bacteria help our bodies stay in balance, while other types can multiply within the body and cause infection. Bacteria are the most common causes of infections in people with cancer. Some examples of bacterial infection include food poisoning, pneumonia, and strep throat.

Chemotherapy (chemo) – Drugs to destroy cancer cells. A person on chemotherapy may take one drug or a combination of drugs. Most often these drugs are given by vein using intravenous (IV) infusion. Some can be taken by mouth or given as an injection, among other methods of delivery.

Co-insurance – Some insurance coverage requires you to pay a percentage of the cost of covered medical services, usually 20–30 percent. Your portion of the cost is the co-insurance.

Colony-stimulating factors – Also called CSFs, colony-stimulating factors are drugs that promote the production of various white blood cells. An example of a CSF is Neulasta® (pegfilgrastim).

Complete blood count (CBC) – The CBC is a test that determines the number of red blood cells, white blood cells, and platelets in the blood.

Co-payment – Also called co-pay, a flat fee for specified medical services required by some insurers. For example, your insurance provider may require you to pay a $10 co-payment for a doctor visit or a $50 co-payment for a hospital stay.

Deductible – The amount you must pay each year for your medical expenses before your insurance policy starts paying. Deductibles are common in fee-for-service coverage and PPOs.

Febrile neutropenia (FN) – Having a low white blood cell count (neutropenia) and a fever (a neutropenic fever). Febrile neutropenia is often a sign of a serious infection.

Infection – An invasion of microorganisms such as bacteria or viruses that have the ability to multiply and cause disease.

Lymphoma – Cancer that begins in cells of the lymphatic system (part of the immune system that produces and stores cells that fight infection and disease).

Myelosuppressive chemotherapy – Sometimes called strong chemotherapy, a type of chemotherapy that can lower the number of blood cells in your body. Often, people just use the word myelosuppressive to mean chemotherapy that lowers your number of white blood cells.

Neutropenia – A lower-than-normal number of neutrophils (infection-fighting white blood cells) in the blood. It is a common side effect of some chemotherapy treatments. Doctors check the number of neutrophils when they measure the white blood cell count, to monitor the risk of infection.

Neutropenic fever – Having a low white blood cell count with a fever may be a sign of serious infection.

Neutrophil – The most common type of white blood cell. Neutrophils help the body fight infection. A low white blood cell count usually indicates that the neutrophil count is low. It is easier to get an infection and harder to recover from an infection when the number of neutrophils in the bloodstream is low.

Neutrophil count – The number of a specific kind of infection-fighting white blood cells called neutrophils in the blood. A low white blood cell count usually indicates that the neutrophil count is low. It is easier to get an infection and harder to recover from an infection when the number of neutrophils in the bloodstream is low.

Oncologist – A doctor who specializes in the treatment of cancer.

Placebo – A "dummy" treatment used in some clinical trials. In these studies, a group of patients who are given a placebo treatment are compared to another group of patients who are given the actual treatment. The difference in results between the actual treatment group and the placebo group are considered the result of giving the medicine.

Platelets – A type of cell made in the bone marrow. The main function of platelets is to aid in clotting the blood following an injury.

Side effect – Any undesired actions or effects of a drug or treatment. For example, common side effects of chemotherapy include fatigue, nausea, vomiting, and loss of appetite.

White blood cell (WBC) – A white blood cell is one of the three main types of blood cells. They are produced in the bone marrow and released into the blood. White blood cells are responsible for fighting infection. There are several kinds of white blood cells, including monocytes, lymphocytes, neutrophils, eosinophils, and basophils.

Expand List
Collapse List

Frequently Asked Questions

About Chemotherapy

About Neulasta®

About Neulasta® Onpro®

For Patients Already on Onpro®: Injector FAQs

Important Safety Information

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:
  • Have a sickle cell disorder
  • Have had severe skin reactions to acrylic adhesives
  • Are allergic to latex – The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
  • Have kidney problems
  • Are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Neulasta®?
  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.
  • A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.
If you have an allergic reaction during the delivery of Neulasta®, remove the on-body injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body injector. Get emergency medical help right away.
  • Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.
  • Kidney injury (glomerulonephritis). Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
  • Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta®.
  • Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Neulasta®. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Neulasta®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
  • Capillary Leak Syndrome. Neulasta® can cause fluid to leak from blood vessels into your body’s tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
    • Swelling or puffiness and are urinating less than usual
    • Trouble breathing
    • Swelling of your stomach area (abdomen) and feeling of fullness
    • Dizziness or feeling faint
    • A general feeling of tiredness
  • Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Neulasta® is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Neulasta®.
  • Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta®. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Neulasta® is pain in your bones and in your arms and legs.

These are not all the possible side effects of Neulasta®. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at 1-800-FDA-1088.

Please see Neulasta® Patient Information.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).